KCL-286 Repairs DNA Damage in Alzheimer’s Mice After Clearing Phase 1 Safety Trial
Updated
Updated · ScienceDaily · Jul 17
KCL-286 Repairs DNA Damage in Alzheimer’s Mice After Clearing Phase 1 Safety Trial
3 articles · Updated · ScienceDaily · Jul 17
Summary
King’s College London reported that KCL-286 repaired DNA damage and reduced brain inflammation in an Alzheimer’s mouse model, pointing to a potential disease-modifying treatment.
The oral small molecule targets multiple early disease pathways at once, including DNA double-strand breaks and inflammation, rather than focusing only on amyloid-beta or tau.
KCL-286 activates a protein in the retinoic acid pathway and was originally developed for spinal cord injury, where earlier work had already shown DNA-repair effects.
Phase 1 human safety and tolerability testing has already been completed for another condition, which researchers said could shorten the timeline for Alzheimer’s clinical trials if the mouse results translate to people.
How can a repurposed spinal cord drug become our best hope for an Alzheimer's cure?
Is repairing DNA damage, not clearing plaques, the real key to defeating Alzheimer's?
Does targeting the vitamin A pathway to treat Alzheimer's pose unforeseen long-term health risks?
KCL-286 Advances to Alzheimer’s Clinical Trials: Targeting DNA Damage and Neuroinflammation for Disease Modification
Overview
KCL-286, developed at King’s College London, is a promising new drug now ready for human clinical trials in Alzheimer’s disease. It is an orally available small molecule that can cross the blood-brain barrier, which is important for treating brain disorders. KCL-286 has already completed Phase 1 safety testing for another medical condition, allowing researchers to use existing human safety data and speed up its development for Alzheimer’s. This initial safety clearance is expected to significantly accelerate the clinical pathway, making KCL-286 a strong candidate for future Alzheimer’s treatments.